CXCL10 and acute lymphoblastic leukemia: These insights illuminate mechanisms of T-ALL neurotropism and identify multiple potential therapeutic targets, including CXCR3, CXCL10, and downstream cytokine pathways, that could be exploited to disrupt leukemic trafficking and retention.